Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Sanofi

A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the New England Journal of Medicine reported on Thursday.

Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial

United Therapeutics

Vertex Pharmaceuticals

The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists.

3 Underappreciated Healthcare Stocks to Buy Now: April 2024

AstraZeneca

Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.

Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion

Costco

Costco and its healthcare partner Sesame have started offering weight-loss drugs including Ozempic to Costco members. Under a $179 three-month prescription plan, members will have access to video consultations with a weight-loss doctor and an individualized, clinically-appropriate treatment program.

Costco begins offering Novo Nordisk's Ozempic to members

ASML Hld

Star Bulk Carriers

Towards the end of the just completed first quarter, U.S.-based hedge funds began dumping American equities and shifting capital into European stocks. In an analysis, investment bank Morgan Stanley (NYSE: MS ) found that hedge funds “have bought EU equities in nearly 70% of the trading sessions” since the European stock market began to rally in January of this year.

Hedge Fund Favorites: 3 European Stocks Attracting Significant U.S. Investment

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?

Hermes International

SAP SE

Siemens AG

Forget AI plays, meme stocks, gold, even cocoa futures — the biggest bull market right now is in equity acronyms.

The Seven Wonders of Europe adds to bull market in acronyms

Eiger BioPharmaceuticals

Viking Therapeutics

Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.

Healthcare stocks fade as obesity-drug optimism fades

Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

AbbVie

HCA Healthcare

Intuitive Surgical

UnitedHealth Group

These seven healthcare companies are industry and market leaders. They generally present excellent long-term prospects, too.

Meet The "Magnificent Seven" of Healthcare Stocks

Novo Nordisk's business is not only growing at a fast rate; it also generates impressive margins. Demand for its products is strong and could increase in the years ahead.

Is Novo Nordisk the Best Healthcare Stock for You?

Novo Nordisk is buying Cardior, a clinical-stage biotech that is developing heart disease drugs. Its cardiovascular disease pipeline will get a lot stronger as a result of the acquisition.

Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock

Omega Therapeutics

Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung cancer, and obesity. Omega Therapeutics has signed a collaboration with Novo Nordisk to develop a drug for obesity management, validating the potential of its platform.

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound, have already generated billions of dollars in revenue but this may be the tip of the iceberg. Viking Therapeutics' VK2735 has emerged as a strong contender in the GLP-1 drug market, with promising weight loss results in clinical studies.

Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data

Catalent

DexCom

Stevanato Group SpA

The diabetes and obesity markets are large and growing, with an estimated total long-term addressable market of $100 billion in the US alone. Denmark's Novo Nordisk and US-based Eli Lilly are leading pharmaceutical companies in the development of GLP-1-based treatments for diabetes and obesity.

International Companies Drive Diabesity Innovation

CVS Health

Elevance Health Inc

The first major U.S. health insurers have agreed to start paying for the popular anti-obesity drug Wegovy for certain people on Medicare with heart-related conditions.

First Medicare Health Plans to Start Paying for Weight-Loss Drug Wegovy

Broadcom

As the stock market rally continues, the trillion-dollar market cap club stands to get just a bit more crowded. Undoubtedly, more than a handful of mega-cap titans could pass the $1 trillion milestone as soon as 2024.

Knocking on the Trillion-Dollar Door: 3 Stocks Ready to Shatter the Market Cap Milestone

Some large health insurers in the U.S. will start covering Wegovy, which has become a popular anti-obesity drug — but not for those using it to lose weight, according to a report by The Wall Street Journal.

Wegovy will be covered by some insurers, but not for weight loss: report

Barron's published an article in February discussing cheap healthcare stocks to buy, noting comments from Janus Henderson Global Life Sciences (MUTF: JAGLX ) co-manager Andy Acker. “At one point in October [2023], we had 232 biotech companies trading below the levels of cash on their balance sheet,” Acker told Barron's.

3 Healthcare Stocks to Buy From 3 of the Best Actively Managed Funds

Altimmune

Amgen

Madrigal Pharmaceuticals

Rhythm Pharmaceuticals

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are answering the urgent need for effective solutions with a new generation of weight loss drugs capable of achieving previously unattainable levels of weight reduction.

7 Stocks That Will Drive the Weight Loss Drugs Market

Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the “outrageously high price has the potential to bankrupt Medicare, the American people and our entire health care system.

Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy

Researchers found Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply, figures that include a profit margin.

Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests

The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the dominance of Novo Nordisk and Eli Lilly is unlikely to be toppled anytime soon.

Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon

FedEx

Zoom Video

As we approach the end of the year's first quarter, the stock market has enjoyed a strong run. Three months into 2024 and the benchmark S&P 500 index is already up 10%.

3 Stocks to Buy for the Next Bull Run: March 2024

Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.

Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline

News for Novo Nordisk Stock (NVO)